Tech Company Financing Transactions
1910 Genetics Funding Round
1910 Genetics, based in Cambridge, secured investment capital from Accenture Ventures.
Transaction Overview
Company Name
Announced On
10/31/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
1910 Genetics is unique in its capability to apply AI to the design of both small molecule and protein therapeutics. ELVIS� is 1910 Genetics' small molecule drug discovery engine, which consists of three AI platforms and one biological assay platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jen Nwankwo
Vice President
Lewis Whitehead
Browse more venture capital transactions:
Prev: 10/31/2024: ContraForce venture capital transaction
Next: 10/31/2024: Buddy.ai venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs